Fluorogenic Platinum(IV) Complexes as Potential Predictors for the Design of Hypoxia-Activated Platinum(IV) Prodrugs Hypoxia (low-oxygen) is one of the most common characteristics of solid tumours. Exploiting tumour hypoxia to reductively activate Pt(IV) prodrugs has the potential to deliver toxic Pt(II) selectively and thus overcome the systemic toxicity issues of traditional Pt(II) therapies. However, our current understanding of the behaviour of Pt(IV) prodrugs in hypoxia is limited.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jevon
Contact Jevon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack